lamotrigine has been researched along with Child Development Deviations in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "to describe the population pharmacokinetics of lamotrigine (LTG) in developmentally disabled (DD) patients with epilepsy and (2) to determine if there is an effect of valproate (VPA) concentration on the extent of the pharmacokinetic interaction between VPA and LTG." | 9.09 | Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ( Anderson, GD; Gidal, BE; Lanning, A; Rutecki, PR; Shaw, R, 2000) |
| "We report the results of an open trial with lamotrigine (LTG) as add-on drug in children and adolescents with refractory epilepsy and mental delay." | 9.08 | Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. ( Coppola, G; Pascotto, A, 1997) |
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 8.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "to describe the population pharmacokinetics of lamotrigine (LTG) in developmentally disabled (DD) patients with epilepsy and (2) to determine if there is an effect of valproate (VPA) concentration on the extent of the pharmacokinetic interaction between VPA and LTG." | 5.09 | Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ( Anderson, GD; Gidal, BE; Lanning, A; Rutecki, PR; Shaw, R, 2000) |
| "We report the results of an open trial with lamotrigine (LTG) as add-on drug in children and adolescents with refractory epilepsy and mental delay." | 5.08 | Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. ( Coppola, G; Pascotto, A, 1997) |
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 4.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter study in the United States and the United Kingdom." | 3.75 | Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2009) |
| "Epilepsy was diagnosed in 54." | 1.62 | The molecular and phenotypic spectrum of CLCN4-related epilepsy. ( Cao, D; Fahlke, C; Guzman, RE; He, H; Peng, J; Sierra-Marquez, J; Stauber, T; Yin, F, 2021) |
| "To study the risk of intellectual disability and delayed development in childhood milestones among children of women who used valproate or other AEDs during pregnancy." | 1.56 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. ( Christensen, J; Daugaard, CA; Dreier, JW; Pedersen, L; Sun, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Daugaard, CA | 1 |
| Pedersen, L | 1 |
| Sun, Y | 1 |
| Dreier, JW | 1 |
| Christensen, J | 1 |
| He, H | 1 |
| Guzman, RE | 1 |
| Cao, D | 1 |
| Sierra-Marquez, J | 1 |
| Yin, F | 1 |
| Fahlke, C | 1 |
| Peng, J | 1 |
| Stauber, T | 1 |
| Kong, L | 1 |
| Zhou, T | 1 |
| Wang, B | 1 |
| Gao, Z | 1 |
| Wang, C | 1 |
| Ogawa, K | 1 |
| Iyoda, K | 1 |
| Verrotti, A | 1 |
| Scaparrotta, A | 1 |
| Cofini, M | 1 |
| Chiarelli, F | 1 |
| Tiboni, GM | 1 |
| Meador, KJ | 1 |
| Baker, GA | 2 |
| Browning, N | 1 |
| Clayton-Smith, J | 2 |
| Combs-Cantrell, DT | 1 |
| Cohen, M | 1 |
| Kalayjian, LA | 1 |
| Kanner, A | 1 |
| Liporace, JD | 1 |
| Pennell, PB | 1 |
| Privitera, M | 1 |
| Loring, DW | 1 |
| Cummings, C | 1 |
| Stewart, M | 1 |
| Stevenson, M | 1 |
| Morrow, J | 1 |
| Nelson, J | 1 |
| Poolos, NP | 1 |
| Warner, LN | 1 |
| Humphreys, SZ | 1 |
| Williams, S | 1 |
| Bromley, RL | 1 |
| Mawer, GE | 1 |
| Briggs, M | 1 |
| Cheyne, C | 1 |
| García-Fiñana, M | 1 |
| Kneen, R | 1 |
| Lucas, SB | 1 |
| Shallcross, R | 1 |
| Piantino, JA | 1 |
| Torres, A | 1 |
| Coppola, G | 1 |
| Pascotto, A | 1 |
| Sunder, TR | 1 |
| Gidal, BE | 1 |
| Anderson, GD | 1 |
| Rutecki, PR | 1 |
| Shaw, R | 1 |
| Lanning, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lamotrigine and Child Development Deviations
| Article | Year |
|---|---|
The risks associated with the use of lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Developmental Disabilities; Excitatory Amino Acid Ant | 2018 |
Developmental neurotoxicity and anticonvulsant drugs: a possible link.
Topics: Animals; Anticonvulsants; Breast Feeding; Carbamazepine; Cognition Disorders; Developmental Disabili | 2014 |
Meeting the challenge of epilepsy in persons with multiple handicaps.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Comorbidity; Developmental Disabilities | 1997 |
2 trials available for lamotrigine and Child Development Deviations
| Article | Year |
|---|---|
Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Developmental Disabilities; Drug Resist | 1997 |
Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.
Topics: Adolescent; Adult; Algorithms; Anticonvulsants; Child; Chromatography, Gas; Chromatography, High Pre | 2000 |
8 other studies available for lamotrigine and Child Development Deviations
| Article | Year |
|---|---|
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Denmark; Developmen | 2020 |
The molecular and phenotypic spectrum of CLCN4-related epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child Behavior Disorders; Child, Preschool; Chlorid | 2021 |
[The effectiveness of lamotrigine in a case of ring chromosome 14 with refractory epilepsy].
Topics: Anticonvulsants; Brain Waves; Child, Preschool; Chromosomes, Human, Pair 14; Developmental Disabilit | 2013 |
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Developmental Disabilities; Dose | 2009 |
Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Case-Control Studies; Child, Preschool; Developmental Disabilities; | 2011 |
Comparative efficacy of combination drug therapy in refractory epilepsy.
Topics: Anticonvulsants; Developmental Disabilities; Drug Therapy, Combination; Epilepsy; Female; Humans; La | 2012 |
The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Child; Child Development Disorders, Per | 2013 |
Myoclonic seizures in a patient with Charcot-Marie-tooth disease.
Topics: Anticonvulsants; Carbamazepine; Charcot-Marie-Tooth Disease; Child; Developmental Disabilities; Drug | 2007 |